Development Strategy

Robust Pipeline Clinical Development Technology Platform Collaborations

Pipeline

Robust Pipeline with global rights and lead positions

Fields	Project/Modality	Target	Indications
Nephropathy	SC0062 SM	ETA	lgA
Nephropathy	SC0062 SM	ETA	DKD
CKD Area，SC0062, a highly ETA-Selective receptor antagonist，has completed phaseⅠ trial in healthy volunteers showing favorable safety profile，no edema reported. SC0062 has the characteristics of high ETA/ETB selection ratio and has the potential make a breakthroughs in CKD ( such as IgA、DKD）.
Oncology	BC3195 ADC	CDH3	Soild tumor
BC3195 represents a groundbreaking first-in-class CDH3-directed antibody drug conjugate that is currently in phase I of clinical trial in China and U.S. This powerful molecule is expertly designed to compose a novel anti-CDH3 mAb, a cleavable linker, and a clinically validated payload with bystander killing effect.
Oncology	BC2027 ADC	GPC3	Solid tumor

Oncology	SC0245 SM	ATR	SCLC
DDR Pathway, SC0245 is the first ATR Kinase small molecule inhibitor IND approved by NMPA，currently in PhaseⅠdose escalation. In preclinical studies, SC0245 has shown favorable safety 、tolerability and pharmacokinetic profiles，and demonstrated high antitumor activity as a single agent or in combination with other agents in a variety of animal models.
Oncology	SC0191 SM	WEE1	OC
DDR Pathway，SC0191 is the first WEE1 Kinase small molecule inhibitor IND approved by NMPA，currently in PhaseⅠdose escalation. In preclinical studies, SC0191 has shown favorable safety profile and demonstrated high antitumor activity as a single agent or in combination with other agents in a variety of animal models.
Oncology	BC3402 mAb	TIM-3	HCC
Immune Checkpoint，BC3402 is a humanized TIM-3 monoclonal antibody, currently in PhaseⅠdose escalation. In Preclinical studies，BC3402 has shown a strong T cell activation and inhibition of Treg，and demonstrated high antitumor activity as a single agent or in combination with other agents in a variety of animal models.
Oncology	BsAb	Undisclosed	Solid tumor

SM=Small Molecule

Highly Differentiated

Science-Driven

Deeply understand the scientific mechanism, and improve the success rate of target selection

Clinically-Oriented

Strive to meet the unmet medical needs of the future and to foresee the trend the future clinical treatment scenarios

Long-term Commerical Value

Develop products with long-term commercial value

Focused Area

From anti-tumor to anti-tumor resistance

Chronic kidney disease(CKD)

Oncology

From anti-tumor to anti-tumor resistance